Clinical Core - Pharmacogenomics of Statin Therapy (POST)

临床核心 - 他汀类药物治疗的药物基因组学 (POST)

基本信息

批准号：
9139484
负责人：
Carlos Iribarren
金额：
$ 50.87万
依托单位：
CHILDREN'S HOSPITAL & RES CTR AT OAKLAND
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9139484
关键词：
Adopted Adult Adverse effects Aging Biomedical Research California Caring Cell model Clinical Clinical Research Cohort Studies Collection Computerized Medical Record Coronary DNA Data Data Set Diabetes Mellitus Disease Electronic Health Record Environment Epidemiologic Studies Event Exposure to Feces Future Genes Genotype Group Practice Guidelines Health Human In Vitro Individual Informatics Lipids Medical Medical Electronics Metabolic Molecular Myopathy Participant Patients Pharmacogenomics Pharmacologic Substance Pharmacy facility Plasma Population Population Heterogeneity Recording of previous events Records Recruitment Activity Research Resources Role Sampling Simvastatin Site Stroke Study Subject System Variant Whole Blood adverse outcome base biobank c new clinical practice cohort database query design ethnic diversity exome follow-up genetic analysis genetic epidemiology genetic information genome wide association study genome-wide health care delivery healthy aging lymphoblastoid cell line member phenotypic data programs prospective racial diversity response socioeconomics transcriptomics

项目摘要

CLINICAL CORE: PROJECT SUMMARY The Clinical Core at the Division of Research, Kaiser Permanente of Northern California (KPNC) is a key component of the overall POST Center. It serves a vital role by providing all the human participants for Project 1, and all the genotypic data, phenotypic data, and DNA samples to Project 3. The aims of the POST Clinical Core are: 1) To obtain whole blood and plasma from KPNC statin users with a) a major adverse coronary event (MACE, N=124) while on treatment, b) statin-induced myopathy (N=124), c) new onset diabetes (N=124), and d) three sets of 124 matched controls (N=372) for the studies in Project 1 (“Molecular Determinants of Statin Efficacy and Adverse Effects using Cellular Models”, Drs. Medina and Krauss); 2) With Project 3 (“Genome-wide Association Study of Statin Response and its Consequences”, Dr. Risch), create a dataset of medical and pharmacy information relevant to statin effects on lipids, MACE, stroke, statin-induced myopathy and new onset diabetes from the electronic medical records of patients in the GERA cohort; and 3) Provide DNA samples from selected statin users within the GERA cohort (n=2,517) and within the extended Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) biorepository (n=843) to Project 3 for follow-up genetic analysis of candidate loci identified throughout the Center's research program.

临床核心：项目摘要北加州凯撒医疗机构 (KPNC) 研究部的临床核心是关键它是整个 POST 中心的组成部分，为项目提供所有人类参与者，发挥着至关重要的作用。 1，以及项目 3 的所有基因型数据、表型数据和 DNA 样本。 POST 临床的目的核心是： 1) 从患有 a) 严重冠状动脉不良反应的 KPNC 他汀类药物使用者处获取全血和血浆治疗期间发生的事件（MACE，N=124），b）他汀类药物诱发的肌病（N=124），c）新发糖尿病 (N=124)，以及 d) 项目 1 中研究的三组 124 个匹配对照 (N=372)（“分子生物学”） 2) 与项目 3（“他汀类药物反应及其后果的全基因组关联研究”，Risch 博士），创建与他汀类药物对血脂、MACE、中风、他汀类药物诱发的影响相关的医学和药学信息数据集来自 GERA 队列中患者电子病历的肌病和新发糖尿病；3) 提供来自 GERA 队列 (n=2,517) 和扩展范围内选定的他汀类药物使用者的 DNA 样本 Kaiser Permanente 基因、环境和健康研究计划 (RPGEH) 生物样本库 (n=843) 项目 3 用于对整个中心研究计划中确定的候选基因座进行后续遗传分析。